At the 2015 annual meeting of the American Society of Hematology (ASH) we heard about some of the latest data in blood cancers such as AML, CLL and Multiple Myeloma.

Dr Ian Flinn ASH15Ian W. Flinn MD, PhD (pictured above) is the Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute in Nashville, TN.

At ASH15, Dr Flinn presented the results for a CLL trial that combined obinutuzumab, an anti-CD20 monoclonal antibody, with venetoclax, a BCL-2 inhibitor. In this episode, he discusses the rational for the combination, some of the challenges with venetoclax and the future direction in the CLL landscape.

In this episode we’re looking at how to make therapies that target our immune system more effective.

Could it be as simple as changing the composition of the bacteria in the gut, the intestinal microbiome that contains a gazillion bugs?

Dr Tom Gajewski

Dr Tom Gajewski from the University of Chicago (pictured above) talks about research from his lab, recently published in Science, that shows the composition of gut bacteria can impact the efficacy of checkpoint inhibitors in animals.

Could this be part of the reason some people respond to checkpoint inhibitors and others don’t?

A pioneer is someone who helps develop something new and prepares the way for others to follow.

We want to harness our immune system to fight and cure cancer. In this episode you’ll hear from two (of the many) pioneers in the field of cancer immunotherapy.

Dr Stephan Grupp CHOP

Dr Stephan Grupp (pictured above) from The Children’s Hospital of Philadelphia is leading the way in developing CAR T cell therapy for children with acute lymphoblastic leukemia (ALL). Dr Grupp (@GruppSteve) is a Professor of Pediatrics at the University of Pennsylvania.

This episode is from the European Cancer Congress that took place in Vienna, Austria from September 25-29, 2015.

Prof Tom Powles ECC 2015 Atezolizumab

You will hear leading experts talk about the latest cancer immunotherapy data. Professor Tom Powles (Barts, London) discusses the exciting data presented for renal and bladder cancer.

Dr Martin Reck ECC 2015Dr Martin Reck (Grosshansdorf, near Hamburg) talks about the lung cancer immunotherapy data presented in Vienna and the new checkpoint inhibitor data at the meeting. He offers his perspective on the importance of quality-of-life in clinical decision making, and what role biomakers may play in Europe.

This episode features excerpts from an interview with Dr Holbrook Kohrt who was leading the way in researching the potential of immune agonists targeting 4-1BB (CD137). It is with great sadness that we must report that since this episode aired, Holbrook Kohrt is no longer with us. He died, aged 38, on February 24, 2016.

Dr Holbrook Kohrt Stanford

In-Memorium Holbrook Kohrt